Cancer vaccines are finally here. How do we get them to patients?

A Phase 3 trial found that the personalized mRNA cancer vaccine intismeran autogene reduced the risk of recurrence or death by 42% when added to pembrolizumab, marking the first time a neoantigen vaccine met a Phase 3 endpoint in cancer. The result shifts the central question from whether personalized vaccines can work to whether health systems can deliver them promptly and affordably. The slow spread of BRCA testing offers a warning: despite its potential to guide prevention and early detection, high prices, restrictive testing rules, and unclear responsibility for the care process kept it from many eligible patients for decades.

Personalized vaccines challenge systems designed for standardized drugs: each requires tumor and blood samples, sequencing, individualized design and manufacturing, scheduled delivery, and long-term follow-up. Separate organizations handle these steps, while regulatory pathways, coverage incentives, and clinical guidelines can delay adoption and drive up costs. The proposed response is to assess the underlying vaccine-design and manufacturing platforms, then extend their use to related cancers with rigorous follow-up evidence. A planned $200 million public-private initiative would develop trial networks and shared data infrastructure; AI could also streamline development and quality control. Integrated care models, multiyear or outcomes-based payment contracts, and faster guideline updates could align incentives and broaden access. The authors argue that planning these systems now is essential so scientific progress translates into patient benefit.